Bevacizumab

You have access
Alternating Oxaliplatin and Irinotecan Chemotherapy Combined With Capecitabine and Bevacizumab for Microsatellite-stable Stage IV Metastatic Colon Cancer With a BRAF V600E Mutation: Two Case Reports Indicating Survival Improvement over Standard Therapy
YAOYI ZHANG, XIAOHUI LI, SHENG LI, ZHIJIAN YANG, ROBERT M. HOFFMAN and CHEN YU

Anticancer Research January 2025, 45 (1) 399-404; DOI: https://doi.org/10.21873/anticanres.17428
You have access
Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
KUNIHIDE MOHRI, HIDENARI NAGAI, TAKAHISA MATSUDA, YOSHINORI IGARASHI and KOJI HIGAI

Anticancer Research September 2024, 44 (9) 3919-3929; DOI: https://doi.org/10.21873/anticanres.17220
You have access
Importance of Atezolizumab Plus Bevacizumab Combination Treatment as First-line Therapy for Immunological Changes in Patients With Unresectable Hepatocellular Carcinoma
KOJIRO KOBAYASHI, HIDENARI NAGAI, TEPPEI MATSUI, TAKAHISA MATSUDA and KOJI HIGAI

Anticancer Research October 2023, 43 (10) 4601-4609; DOI: https://doi.org/10.21873/anticanres.16654
Open Access
Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience
TAKESHI FUKUDA, TAKUYA NODA, EIJIRO UCHIKURA, YUICHIRO AWAZU, REIKO TASAKA, KENJI IMAI, MAKOTO YAMAUCHI, TOMOYUKI ICHIMURA, TOMOYO YASUI and TOSHIYUKI SUMI

Anticancer Research July 2023, 43 (7) 3097-3105; DOI: https://doi.org/10.21873/anticanres.16481
You have access
Emetogenicity and Risk Factors of Nausea and Vomiting in Patients With Metastatic Colorectal Cancer Receiving Trifluridine/Tipiracil and Bevacizumab Chemotherapy
SERIKA MATSUOKA, HIRONORI FUJII, HIROTOSHI IIHARA, KOICHI OHATA, CHIEMI HIROSE, DAICHI WATANABE, SHIORI SADAKA, SHIGERU KIYAMA, AKITAKA MAKIYAMA, TAKAO TAKAHASHI, RYO KOBAYASHI, NOBUHISA MATSUHASHI and AKIO SUZUKI

Anticancer Research May 2023, 43 (5) 2351-2357; DOI: https://doi.org/10.21873/anticanres.16400
Open Access
Relationship Between Safety and Cumulative Bevacizumab Dose in Patients With Metastatic Colorectal Cancer Who Received Long-term Bevacizumab Treatment
SATOSHI FUKUDA, YUSUKE NIISATO, MIKI TSUJI, SOMA FUKUDA, YUYA HAGIWARA, TSUBASA ONODA, HIROSUMI SUZUKI, YOSHITAKA TANGE, TAKESHI YAMADA, YOSHIYUKI YAMAMOTO and TOSHIKAZU MORIWAKI

Anticancer Research May 2023, 43 (5) 2085-2090; DOI: https://doi.org/10.21873/anticanres.16369
Open Access
Atezolizumab Retains Cellular Binding to Programmed Death Ligand 1 Following Aerosolization via Mesh Nebulizer
GINTARAS ZALESKIS, MARTYNAS TALAIKIS, DAINIUS CHARACIEJUS, VINCAS URBONAS, PAULIUS BOSAS, ADAS DARINSKAS, LAVIJA ZIBUTYTE, LUKAS SIMKUS, ZILVINAS SURVILA, JURGITA JURSENAITE and MARGARITA ZVIRBLE

Anticancer Research March 2023, 43 (3) 1065-1072; DOI: https://doi.org/10.21873/anticanres.16251
Open Access
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
MARINA ABE, TADAHIRO SHOJI, YOHEI CHIBA, ERIKO TAKATORI, YOSHITAKA KAIDO, TAKAYUKI NAGASAWA, MASAHIRO KAGABU, FUMIAKI TAKAHASHI, TAKESHI AIDA and TSUKASA BABA

Anticancer Research March 2023, 43 (3) 1265-1272; DOI: https://doi.org/10.21873/anticanres.16273
You have access
Bevacizumab Plus Carboplatin Plus Nab-paclitaxel for Non-squamous Non-small Cell Lung Cancer in a Real-world Setting
AKIHIRO TAMIYA, MOTOHIRO TAMIYA, YUJI INAGAKI, YOSHIHIKO TANIGUCHI, KEIKO NAKAO, YOSHINOBU MATSUDA, TAKAHISA KAWAMURA, KEI KUNIMASA, TAKAKO INOUE, KAZUMI NISHINO and KYOICHI OKISHIO

Anticancer Research March 2023, 43 (3) 1325-1330; DOI: https://doi.org/10.21873/anticanres.16280
You have access
Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients
YEN-HAO CHEN, YEN-YANG CHEN, JING-HOUNG WANG and CHAO-HUNG HUNG

Anticancer Research March 2023, 43 (3) 1377-1384; DOI: https://doi.org/10.21873/anticanres.16286

Main menu

User menu

Search

Bevacizumab

Pages